Business Wire

FL-GEG

9.7.2021 19:10:10 CEST | Business Wire | Press release

Share
Global Equestrian Group, Waterland Private Equity, and Wellington Equestrian Partners Join Forces to Invest in the Globalization of Equestrian Sport

Andreas Helgstrand, CEO of Global Equestrian Group (GEG), and Mark Bellissimo, CEO of Wellington Equestrian Partners (WEP), announced an unprecedented partnership focused on developing international equestrian sport. GEG will acquire the Wellington, Florida-based Palm Beach International Equestrian Center (PBIEC) and will invest in WEP equestrian lifestyle initiatives. WEP’s largest partners, Mark Bellissimo, Roger Smith, Lisa Lourie, and Marsha Dammerman as well as Michael Stone will co-invest in GEG. Mark Bellissimo and PBIEC have transformed Wellington into the world’s premiere destination for equestrian enthusiasts, with competitions and events across more than 40 weeks every year. PBIEC is home to the Winter Equestrian Festival, spanning 13 weeks and is the world’s largest and longest-running equestrian sports event. 4,000 families, 8,000 horses, and 250,000 spectators from 43 different countries converge on Wellington to compete for over USD 12 million in prize money. A recent independent economic study highlighted the Winter Equestrian Festival’s annual economic impact on Palm Beach County of USD 279 million of total expenditures and 150,000 bed nights. GEG is part of Waterland Private Equity, who manage a global investment portfolio in excess of USD 11 billion.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210709005400/en/

PBIEC operates 16 competition arenas, 2,500 stalls, and provides participants and spectators with a variety of exclusive restaurants, shopping, hospitality areas, and other first-class facilities. PBIEC management will remain intact with Mark Bellissimo continuing as CEO, Michael Stone as President, and David Burton as Chief Operating officer. The GEG initiative will launch major investments in all areas of the facility ensuring that PBIEC will continue to be the pre-eminent sport horse venue in the world with increased exposure in Europe, Asia, and South America. The purchase includes an 11-acre expansion of the Showgrounds. To ensure continuity, the WEP partners required a 50-year deed restriction on the venue that guarantees USEF and FEI sanctioned shows on the property. USEF CEO, Bill Moroney, commented, “As always, we are pleased to see a continued investment in US equestrian sport. This significant commitment to world class facilities, horse and rider welfare, and USEF and FEI competitions further validates the market’s demand, at all levels, for organized sport.” Andreas Helgstrand, co-owner and CEO of GEG added, “The Winter Equestrian Festival and PBIEC are fantastic brands within international equestrian sport. Together, we will strengthen the offering and create a global market leader spreading our passion for equestrian sport and lifestyle to new markets.” Outside of equestrian events the Group is active in other equestrian investments including Helgstrand Dressage, Ludger Beerbaum Stables, Helgstrand Jewellery, and the equestrian apparel and accessories company Kingsland Equestrian. At present, the total revenue of these combined is USD180 million.

GEG will now have event venues in the US, Germany, and Denmark. The partnership will benefit from knowledge sharing and a strengthened positioning of PBIEC within show jumping where Ludger Beerbaum Stables has a unique market position. Furthermore, the partnership enables the Group to leverage PBIEC’s experience and create a European equestrian sports event company. ”Our goal is to enhance equestrian sport by providing superior venues and top sport so riders across the world can live out their passions and dreams. With the acquisition of PBIEC, we now have the perfect setting to do this in the US and with our current expansion of Riesenbeck International in Germany we will have two top professional and attractive show grounds,” says Ludger Beerbaum, four-time Olympic gold medalist in jumping and co-owner of Global Equestrian Group. Bellissimo added, “We are pleased to be collaborating with both Andreas and Ludger, whose passion and commitment to equestrian sport is extraordinary. Opportunities abound to take the sport to a new level.” GEG and WEP are evaluating further investment opportunities in Wellington including a new state-of-the-art Global Dressage Festival showgrounds. Bellissimo will be announcing a comprehensive strategy and a series of investments to elevate Wellington as the World’s premiere equestrian lifestyle destination thus strengthening its international appeal. "The acquisition of PBIEC establishes Global Equestrian Group as a true global market leader in equestrian sports with a strong financial foundation and exciting growth opportunities,” says Kaspar Kristiansen, Managing Director, Waterland Nordic.

About Palm Beach International Equestrian Center
Palm Beach International Equestrian Center (PBIEC) was founded by Mark Bellissimo and Wellington Equestrian Partners in 2006 and has contributed to transforming both equestrian sport and Wellington, Florida’s position as the world’s premiere destination for equestrian enthusiasts. PBIEC arranges 40 weeks of events and operates the Winter Equestrian Festival through its management company, Equestrian Sport Productions. The Winter Equestrian Festival, held over 13 weeks, is the world’s largest and longest-running equestrian sports event with more than 8,000 horses and participants from 50 states and 43 countries. Over 250,000 spectators attend the events. www.pbiec.com

About Global Equestrian Group
Global Equestrian Group is the world’s leading equestrian sports group based on a strategic partnership between internationally acclaimed Helgstrand and Ludger Beerbaum Stables as well as Palm Beach International Equestrian Center and private equity firm Waterland. The Group has 250 full-time employees. Global Equestrian Group has activities in dressage, show jumping and events as well as the jewellery company Helgstrand Jewellery and equestrian apparel and accessories company Kingsland Equestrian as well as other equestrian sports investments. www.globalequestriangroup.com

About Waterland
Waterland is an independent private equity investment group that supports entrepreneurs in realizing their growth ambitions. With substantial financial resources from the firm’s eighth fund of EUR 2.6 billion and committed industry expertise, Waterland enables its portfolio companies to achieve accelerated growth both organically and through acquisitions. To date, Waterland has made investments in over 700 companies. Waterland consistently achieve top tier investment ratings among private equity firms and is the only fund that has consistently been in the top 5 in the HEC/Dow Jones Private Equity Performance Ranking for 10 years. Waterland manages more than EUR 9 billion of investor commitments and has offices in Denmark, the Netherlands, Belgium, Germany, Switzerland, Poland, France, Ireland, and the UK. www.waterland.nu

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye